Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Mar 4;10.1002/ddr.21656.
doi: 10.1002/ddr.21656. Online ahead of print.

Angiotensin Receptor Blockers as Tentative SARS-CoV-2 Therapeutics

Affiliations
Free PMC article

Angiotensin Receptor Blockers as Tentative SARS-CoV-2 Therapeutics

David Gurwitz. Drug Dev Res. .
Free PMC article

Abstract

At the time of writing this commentary (February 2020), the coronavirus COVID-19 epidemic has already resulted in more fatalities compared with the SARS and MERS coronavirus epidemics combined. Therapeutics that may assist to contain its rapid spread and reduce its high mortality rates are urgently needed. Developing vaccines against the SARS-CoV-2 virus may take many months. Moreover, vaccines based on viral-encoded peptides may not be effective against future coronavirus epidemics, as virus mutations could make them futile. Indeed, new Influenza virus strains emerge every year, requiring new immunizations. A tentative suggestion based on existing therapeutics, which would likely be resistant to new coronavirus mutations, is to use available angiotensin receptor 1 (AT1R) blockers, such as losartan, as therapeutics for reducing the aggressiveness and mortality from SARS-CoV-2 virus infections. This idea is based on observations that the angiotensin-converting enzyme 2 (ACE2) very likely serves as the binding site for SARS-CoV-2, the strain implicated in the current COVID-19 epidemic, similarly to strain SARS-CoV implicated in the 2002-2003 SARS epidemic. This commentary elaborates on the idea of considering AT1R blockers as tentative treatment for SARS-CoV-2 infections, and proposes a research direction based on datamining of clinical patient records for assessing its feasibility.

Keywords: AT1R blockers; COVID-19 epidemic; SARS-CoV-2; angiotensin-converting enzyme 2 (ACE2); losartan.

Conflict of interest statement

The author declares no potential conflict of interest.

Similar articles

See all similar articles

Cited by 32 articles

See all "Cited by" articles

References

    1. Beigel J. H., Nam H. H., Adams P. L., Krafft A., Ince W. L., El‐Kamary S. S., & Sims A. C. (2019). Advances in respiratory virus therapeutics—A meeting report from the 6th isirv Antiviral Group conference. Antiviral Research, 167, 45–67. 10.1016/j.antiviral.2019.04.006 - DOI - PMC - PubMed
    1. Belongia E. A., Skowronski D. M., McLean H. Q., Chambers C., Sundaram M. E., & De Serres G. (2017). Repeated annual influenza vaccination and vaccine effectiveness: Review of evidence. Expert Review of Vaccines, 16(7), 1–14. 10.1080/14760584.2017.1334554 - DOI
    1. Chen Y., Guo Y., Pan Y., & Zhao Z. J. (2020). Structure analysis of the receptor binding of 2019‐nCoV. Biochemical and Biophysical Research Communications. 10.1016/j.bbrc.2020.02.071 [Epub ahead of print]. - DOI
    1. Cheng Z. J., & Shan J. (2020). 2019 Novel coronavirus: Where we are and what we know. Infection. 10.1007/s15010-020-01401-y [Epub ahead of print]. - DOI
    1. Deppe S., Böger R. H., Weiss J., & Benndorf R. A. (2010). Telmisartan: A review of its pharmacodynamic and pharmacokinetic properties. Expert Opinion on Drug Metabolism & Toxicology, 6(7), 863–871. 10.1517/17425255.2010.494597 - DOI - PubMed

LinkOut - more resources

Feedback